MMW - Fortschritte der Medizin

, Volume 160, Issue 21–22, pp 65–69 | Cite as


Bei Diabetikern an eine Osteoporose denken!

  • Stephan ScharlaEmail author

Diabetes mellitus Typ 2 — und in noch größerem Maß Typ 1 — führt zu strukturellen Veränderungen des Knochens und zu einem erhöhten Frakturrisiko. Deshalb sollten Sie bei diesen Diabetesformen und zusätzlichen Risikofaktoren wie z. B. höheres Alter eine Osteoporose abklären.

Diabetes mellitus and osteoporosis: Who should be addressed and how to confirm the diagnosis


Diabetes mellitus osteoporosis fracture risk 


  1. 1.
    Neumann T. Knochenstoffwechsel, Umbaumarker und Diabetes. Osteologie 2014;23:91–96CrossRefGoogle Scholar
  2. 2.
    Janghorbani M, Van Dam RM, Willet WC, et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007;166:495–505CrossRefGoogle Scholar
  3. 3.
    Hothersall EJ, Livingstone SJ, Looker HC, et al. Contemporary Risk of Hip Fracture in Type 1 and Type 2 Diabetes: A National Registry Study from Scotland. J Bone Miner Res 2014;29:1054–1060CrossRefGoogle Scholar
  4. 4.
    Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 2005;48:1292–1299CrossRefGoogle Scholar
  5. 5.
    Zhukouskaya VV, Eller-Vainicher C, Vadzianava VV, Shepelkevich AP, Zhurava IV, Korolenko GG, Salko OB, Cairoli E, Beck-Peccoz P, Chiodini I. Prevalence of morphometric vertebral fractures in patients with type 1 diabetes. Diabetes Care 2013;36:1635–1640CrossRefGoogle Scholar
  6. 6.
    Wyers CE, Vranken L, van der Velde RY, Geusens PPMM, Janzing HMJ, Morrenhof JW, van den Bergh JPW. Cardiovascular Risk Factor Analysis in Patients with a Recent Clinical Fracture at the Fracture Liaison Service. BioMed Research International 2014; 2014:710945. doi: 10.1155/2014/710945. Epub 2014 Aug 27.CrossRefGoogle Scholar
  7. 7.
    Wallander M, Axelsson KF, Nilsson AG, Lundh D, Lorentzon M. Type 2 Diabetes and Risk of Hip Fractures and Non-Skeletal Fall Injuries in the Elderly: A Study From the Fractures and Fall Injuries in the Elderly Cohort (FRAILCO). J Bone Miner Res 2017;32:449–460CrossRefGoogle Scholar
  8. 8.
    Napoli N, Schwartz AV, Schafer A, Vittinghoff E, Cawthon PM, Parimi N, Orwoll E, Strotmeyer ES, Hoffman AR Barrett-Connor E, Black DM, for the Osteoporotic Fractures in Men (MrOS) Study Research Group. Vertebral Fracture Risk in Diabetic Elderly Men: The MrOS Study. Journal of Bone and Mineral Research 2018;33:63–69CrossRefGoogle Scholar
  9. 9.
    Jia P, Bao L, Chen H, Yuan J, Liu W, Feng F, Li J, Tang H. Risk of low-energy fracture in type 2 diabetes patients: a meta-analysis of observational studies. Osteoporos Int 2017;28:3113–3121CrossRefGoogle Scholar
  10. 10.
    Kiyohara N, Yamamoto M, Sugimoto T. Discordance between Prevalent Vertebral Fracture and Vertebral Strength Estimated by the Finite Element Method Based on Quantitative Computed Tomography in Patients with Type 2 Diabetes Mellitus. PloS ONE 2015;10(12):e0144496. doi: 10.1371/journal.pone.0144496. eCollection 2015Google Scholar
  11. 11.
    Jung JK, Kim HJ, Lee HK, et al. Fracture Incidence and Risk of Osteoporosis in Female Type 2 Diabetic Patients in Korea. Diabetes Metab J 2012;36:144CrossRefGoogle Scholar
  12. 12.
    Forsen L, Meyer HE, Midthjell K, Edna TH. Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trondelag Health Survey. Diabetologia 1999;42:920CrossRefGoogle Scholar
  13. 13.
    Napoli N, Strotmeyer ES, Ensrud KE, et al. Fracture risk in diabetic elderly men: the MrOS study. Diabetologia 2014;57:2057–65CrossRefGoogle Scholar
  14. 14.
    Botolin S, McCabe LR. Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. Journal of Cellular Biochemistry 2006;99:411–424CrossRefGoogle Scholar
  15. 15.
    Hough FS, Pierroz DD, Cooper C, Ferrari SL, and the IOF CSA Bone and Diabetes Working Group. European Journal of Endocrinology 2016;174:R127–R138CrossRefGoogle Scholar
  16. 16.
    Schwartz A, Garnero P, Hi Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 94:2380–2386Google Scholar
  17. 17.
    Li C-I, Liu C-S, Lin W-Y, Men N-H, Chen C-S, Yang S-Y, Chen H-J, Lin C-C, Li T-C. Glycated hemoglobin level and risk of hip fracture in older people with type 2 diabetes: a competing risk analysis of taiwan diabetes cohort study. J Bone Miner Res 2015;30:1338–1346CrossRefGoogle Scholar
  18. 18.
    Scharla S. Osteoporose bei Typ -1- und Typ-2-Diabetes mellitus. Arthritis + rheuma 2017;37:395–400CrossRefGoogle Scholar
  19. 19.
    Goulding A, Taylor RW. Plasma leptin values in relation to bone mass and densitiy and to dynamic biochemical markers of bone resorption and formation in postmenopausal women. Calcif Tissue Int 1998;63:456–458CrossRefGoogle Scholar
  20. 20.
    Lacombe J, Cairns BJ, Green J, Reeves GK, Beral V, Armstrong MEG, for the Million Women Study collaborators. The effects of age, adiposity, and physical activity on the risk of seven site-specific fractures in postmenopausal women. J Bone Miner Res 2016;31:1559–1568CrossRefGoogle Scholar
  21. 21.
    Ishii S, Cauley JA, Greendale GA, Nielsen C, Karvonen-Gutierrez C, Ruppert K, Karlamangla AS. Pleiotropic Effects of Obesity on Fracture Risk: The Study of Women’s Health Across the Nation. J Bone Miner Res 2014;29:2561–2570CrossRefGoogle Scholar
  22. 22.
    Johansson H, Kanis JA, Oden A, McCloskey E, Chapurlat RD, Christiansen C, Cummings SR, Diez-Perez A, Eisman JA, Fujiwara S, Glüer CC, Goltzman D, Hans D, Khaw K-T, Krieg MA, Kröger H, LaCroix AZ, Lau E, Leslie WD, Mellström D, Melton III LJ, O’Neill TW, Pasco JA, Prior JC, Reid DM, Rivadeneira F, van Staa T, Yoshimura N, Zillikens MC. A Meta-Analysis of the association of fracture risk and body mass index in women. J Bone Miner Res 2014;29:223–233CrossRefGoogle Scholar
  23. 23.
    Chandran M. Diabetes Drug Effects on the Skeleton. Calcif Tissue Int 2017;100:133–149CrossRefGoogle Scholar
  24. 24.
    Monami M, Antenore A, Dicembrini I, Mannucci E. Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures. A meta-analysis of randomized clinical trials. Diab Care 2011;34:2474–2476CrossRefGoogle Scholar
  25. 25.
    Dombrowski S, Kostev K, Jacob L. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany - A retrospective analysis of real-world data. Osteoporos Int 2017; 28:2421–2428CrossRefGoogle Scholar
  26. 26.
    Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney International 2014;85:962–971CrossRefGoogle Scholar
  27. 27.
    Hadjidakis D, Androulakis II, Mylonakis AM, Sfakianakis ME, Raptis AE, Papaefstathiou AG, Economopoulos TC, Raptis SA. Diabetes in postmenopause: different influence on bone mass according to age and disease duration. Exp Clin Endocrinol Diabetes 2009;117:199CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Bad ReichenhallDeutschland

Personalised recommendations